Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan

NEW YORK, January 7, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), and Mylan, Inc. (NASDAQ: MYL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Celgene Corporation Research Report

On January 2, 2014, Celgene Corporation (Celgene) announced that it will present at the 32^nd Annual J.P. Morgan Healthcare Conference on January 13, 2014 at 11:00 a.m. ET. The Company added that the presentation will be webcast live and can be accessed through Investor Relations section of its website. Celgene stated that its management will give an overview of the Company's business and financial outlook at the conference. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/7f47_CELG

Merck & Co. Inc. Research Report

On January 2, 2014, Merck & Co. Inc.'s (Merck) stock declined 1.12%, ending the day at $49.49. Over the previous three trading sessions, shares of Merck went down by 0.60%, compared to the Dow Jones Industrial Average which declined 0.22% during the same period. The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/430d_MRK

Bristol-Myers Squibb Company Research Report

On December 19, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) announced that it signed an agreement under which it will sell its global diabetes business which was part of the Company's partnership with AstraZeneca. The Company stated that in accordance with the agreement, AstraZeneca will make an upfront payment of $2.7 billion to Bristol-Myers Squibb, along with potential regulatory- and sales-based milestone payments of up to $1.4 billion, while also making royalty payments based on net sales through 2025. Bristol-Myers Squibb added that AstraZeneca will also make payments of up to $225 million if and when certain assets are subsequently transferred. The Company stated that the transaction was approved by its Board of Directors. The Company provided its 2014 non-GAAP EPS guidance of $1.65 to $1.80. Lamberto Andreotti, CEO, Bristol-Myers Squibb, commented, "This agreement will allow us to further evolve our business model as a leading specialty BioPharma company and increase resources behind the opportunities that drive the greatest long-term value for patients, our company and our shareholders. Today's announcement puts the diabetes franchise in the capable hands of AstraZeneca and allows us to move to a more simplified operating model consistent with our pipeline and portfolio." The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/81a9_BMY

Valeant Pharmaceuticals International, Inc. Research Report

On January 2, 2014, Valeant Pharmaceuticals International, Inc.'s (Valeant) stock lost 0.36%, ending the day at $116.98. Over the previous three trading sessions, shares of Valeant increased 2.98%, compared to the Dow Jones Industrial Average, which declined 0.22% during the same period. The Full Research Report on Valeant Pharmaceuticals International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/9fdd_VRX

Mylan, Inc. Research Report

On January 2, 2014, Mylan, Inc. (Mylan) announced the appointment of Rakesh Bamzai as President, India Commercial and Emerging Markets. Mylan President Rajiv Malik said, "We were extremely pleased when Rakesh asked to join our company. Many of us at Mylan have had a firsthand opportunity to work with Rakesh over the course of our strategic partnership with Biocon and have observed his strong business and marketing acumen, his strategic insight and outstanding leadership skills. In this new role overseeing all of Mylan's commercial operations in India and emerging markets, we believe that Rakesh will add significant value to Mylan." The Company informed that Bamzai has over 20 years of experience in the Indian and global biopharmaceutical industry, and was President of Marketing at Biocon, before joining Mylan. The Full Research Report on Mylan, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5a20_MYL

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

1. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
2. For any urgent concerns or inquiries, please contact us at [email protected].
3. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED